FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death

Blood

Volumn 118, Issue 26, 2011, Pages 6893-6903

  Alinari, Lapo ^a   Mahoney, Emilia ^a   Patton, John ^a   Zhang, Xiaoli ^b   Huynh, Lenguyen ^b   Earl, Christian T ^a   Mani, Rajeswaran ^a   Mao, Yicheng ^a   Yu, Bo ^c   Quinion, Carl ^a   Towns, William H ^a   Chen, Ching Shih ^b   Goldenberg, David M ^d   Blum, Kristie A ^a   Byrd, John C ^a   Muthusamy, Natarajan ^a   Prætorius Ibba, Mette ^b   Baiocchi, Robert A ^a,e  

^a BAYLOR UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Ohio State University   (United States)

^d CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^e A458 Starling Loving Hall   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD74 ANTIGEN; CHLOROQUINE; FINGOLIMOD; MILATUZUMAB; PROTEIN P62; RAPAMYCIN; SODIUM CHLORIDE; TRASTUZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOLYSOSOME; AUTOPHAGY; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOMA CELL; LYSOSOME MEMBRANE; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 84255176452     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-363879     Document Type: Article

References (47)

1. Zelenetz AD. Mantle cell lymphoma: an update on management. Ann Oncol. 2006;17(suppl 4): iv12-iv14. (Pubitemid 43778969)
2. Peaposrez-Galaaposn P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117(1):26-38.
3. Martínez N, Camacho FI, Algara P, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res. 2003;63(23):8226-8232. (Pubitemid 37549472)
4. Rudelius M, Pittaluga S, Nishizuka S, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood. 2006;108(5):1668-1676. (Pubitemid 44316136)
5. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171(1):88-95. (Pubitemid 36745276)
6. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3(2):185-197. (Pubitemid 37443390)
7. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002; 296(5566):346-349. (Pubitemid 34303689)
8. Tedesco-Silva H, Mourad G, Kahan BD, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation. 2005; 79(11):1553-1560. (Pubitemid 40847587)
9. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402- 415.
10. Liu Q, Alinari L, Chen CS, et al. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res. 2010; 16(12):3182-3192.
11. Matza D, Wolstein O, Dikstein R, Shachar I. Invariant chain induces B cell maturation by activating a TAF(II)105-NF-kappaB-dependent transcription program. J Biol Chem. 2001;276(29): 27203-27206.
12. Starlets D, Gore Y, Binsky I, et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood. 2006;107(12): 4807-4816. (Pubitemid 43882632)
13. Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007;13(18): 5556s-5563s. (Pubitemid 47510387)
14. Alinari L, Yu B, Christian BA, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011;117(17):4530-4541.
15. Omar HA, Chou CC, Berman-Booty LD, et al. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology. 2011;53(6):1943-1958.
16. Swerdlow S, Campo E, Harris NL, eds.; International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Geneva, Switzerland: World Health Organization; 2008.
17. Drexler HG, MacLeod RA. Mantle cell lymphomaderived cell lines: unique research tools. Leuk Res. 2006;30(8):911-913. (Pubitemid 43831194)
18. Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood. 2008;112(13): 5180-5189.
19. Alinari L, White VL, Earl CT, et al. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs. 2009; 1(1):31-40.
20. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular selfdigestion. Nature. 2008;451(7182):1069-1075. (Pubitemid 351317450)
21. Levine B, Yuan J. Autophagy in cell death: an innocent convict? J Clin Invest. 2005;115(10):2679- 2688.
22. Zhang N, Qi Y, Wadham C, et al. FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy. Autophagy. 2010;6(8):1157-1167.
23. Wallington-Beddoe CT, Hewson J, Bradstock KF, Bendall LJ. FTY720 produces caspaseindependent cell death of acute lymphoblastic leukemia cells. Autophagy. 2011;7(7):707-715.
24. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19(21):5720-5728.
25. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell. 2010; 140(3):313-326.
26. Pattingre S, Tassa A, Qu X, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122(6):927-939. (Pubitemid 41345209)
27. Pankiv S, Clausen TH, Lamark T, et al. p62/ SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. 2007;282(33):24131- 24145.
28. Lai R, McDonnell TJ, O'Connor SL, et al. Establishment and characterization of a new mantle cell lymphoma cell line, Mino. Leuk Res. 2002; 26(9):849-855. (Pubitemid 34778500)
29. Jeon HJ, Kim CW, Yoshino T, Akagi T. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol. 1998;102(5): 1323-1326. (Pubitemid 28435219)
30. M'Kacher R, Farace F, Bennaceur-Griscelli A, et al. Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model. Cancer Genet Cytogenet. 2003;143(1):32-38. (Pubitemid 36549005)
31. Estrov Z, Talpaz M, Ku S, et al. Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. Leuk Res. 1998;22(4):341-353. (Pubitemid 28271411)
32. Boya P, Gonzalez-Polo RA, Casares N, et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol. 2005;25(3):1025-1040. (Pubitemid 40165810)
33. Takeuchi H, Kondo Y, Fujiwara K, et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 2005;65(8):3336-3346. (Pubitemid 40524618)
34. Chang CL, Ho MC, Lee PH, Hsu CY, Huang WP, Lee H. S1P(5) is required for sphingosine 1-phosphate-induced autophagy in human prostate cancer PC-3 cells. Am J Physiol Cell Physiol. 2009;297(2):C451-C458.
35. Kroemer G, Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer. 2005;5(11):886-897. (Pubitemid 41746033)
36. Reich M, Wieczerzak E, Jankowska E, Palesch D, Boehm BO, Burster T. Specific cathepsin B inhibitor is cell-permeable and activates presentation of TTC in primary human dendritic cells. Immunol Lett. 2009; 123(2):155-159.
37. Yasui H, Hideshima T, Raje N, et al. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res. 2005; 65(16):7478-7484. (Pubitemid 41161283)
38. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome- positive acute lymphocytic leukemia. J Clin Invest. 2007;117(9):2408-2421. (Pubitemid 47494343)
39. Liu Q, Zhao X, Frissora F, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/ lymphoma. Blood. 2008;111(1):275-284.
40. Suzuki S, Enosawa S, Kakefuda T, Amemiya H, Hoshino Y, Chiba K. Long-term graft acceptance in allografted rats and dogs by treatment with a novel immunosuppressant, FTY720. Transplant Proc. 1996;28(3):1375-1376. (Pubitemid 26195927)
41. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation. 1996;61(2):200-205. (Pubitemid 26046580)
42. Stein R, Qu Z, Cardillo TM, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood. 2004;104(12):3705-3711. (Pubitemid 39564448)
43. Kaufman JL, Niesvizky R, Stadtmauer EA, et al. Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma [abstract]. J Clin Oncol. 2009;27(15 suppl): 8593.
44. Levine B. Cell biology: autophagy and cancer. Nature. 2007;446(7137):745-747. (Pubitemid 46582063)
45. Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest. 2007;117(2):326-336. (Pubitemid 46203961)
46. Kågedal K, Zhao M, Svensson I, Brunk UT. Sphingosine- induced apoptosis is dependent on lysosomal proteases. Biochem J. 2001;359(2):335- 343.
47. Boya P, Andreau K, Poncet D, et al. Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med. 2003;197(10):1323-1334. (Pubitemid 36617779)